TECHNE Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. TECHNE Corporation, along with its subsidiaries, is engaged in the development, manufacture, and sale of biotechnology products and hematology calibrators and controls. The Company’s activities are conducted, through its wholly owned subsidiaries, Research and Diagnostic Systems, Inc. (R&D Systems), and BiosPacific, Inc. (BioPacific). The Company distributes the biotechnology products in Europe, through its wholly owned United Kingdom-based subsidiary, R&D Systems Europe Ltd. (R&D Europe). The Company distributes biotechnology products in the People’s Republic of China, through its wholly owned subsidiary, R&D Systems China, Co. Ltd. (R&D China). The Company operates in three business segments: biotechnology, R&D Europe and hematology.

Alimera Sciences' tunnel vision is a real asset. The biopharmaceutical company specializes in prescription ophthalmic pharmaceuticals, particularly those aimed at treating ocular diseases affecting the retina. Alimera's most advanced product candidate, Iluvien, is an insert about the size of a grain of rice that slowly releases a drug to the back of the eye used in the treatment of diabetic macular edema (DME); DME, a retinal disease affecting diabetics, can lead to severe vision loss and blindness. Iluvien is effective for up to 36 months and may also have the potential to affect other ophthalmic diseases, such as retinal vein occlusion (RVO). Alimera Sciences is looking to go public through an $80 million IPO.

Phase Bioscience is a biotechnology firm that has developed a technology utilizing genetically-engineered biopolymer peptides (ELPs) that changes solubility (from a liquid to a solid and back) based on the temperature and the salt content of the solution. Known as deltaPhase, Phase Bioscience's ELPs are designed to be used by pharmaceutical researchers in drug discovery processes and in life science applications, including recombinant protein purification (isolating a particular protein in a solution) and enzyme biocatalysts (isolating a particular recombinant enzyme in a solution).

Amylin Pharmaceuticals was founded in 1987 and is based in San Diego, California. Amylin Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. As of December 31, 2008, the Company was marketing two medicines to treat diabetes: BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. In addition to its marketed products, the Company is working with Eli Lilly and Company (Lilly) and Alkermes, Inc. (Alkermes) to develop exenatide once weekly. The Company maintains a discovery research program focused on peptide and protein therapeutics.

Biodel Inc. company was founded in 2003 and is headquartered in Danbury, Connecticut. Biodel Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes. The company develops its product candidates by utilizing its proprietary VIAdel technology that allows to study the interaction between peptide hormones and small molecules. Its product candidates include VIAject, an injectable formulation of recombinant human insulin, which has completed two pivotal Phase III clinical trials for the treatment of Type 1 and Type 2 diabetes; and VIAtab, a sublingual tablet formulation of insulin, which has completed Phase I clinical trial for Type 1 diabetes.

DiagnoCure Inc. company was founded in 1994 and is headquartered in Quebec City, Canada. DiagnoCure, Inc., a life sciences company, engages in the research, development, production, and commercialization of diagnostic tests for the detection and management of cancers in Canada. It focuses on colon, prostate, breast, and lung cancers. The company provides ImmunoCyt /uCyt+, a tool for the diagnosis and monitoring of bladder cancer; uPM3, a noninvasive test for the detection of prostate cancer; and molecular diagnostic tests for lung cancer. It also offers Previstage GCC colorectal cancer staging test for the management of colorectal cancer. The company holds worldwide diagnostic and therapeutic rights for the use of the PCA3 technology in prostate cancer diagnosis. DiagnoCure has a strategic alliance with Gen-Probe Incorporated for the development and commercialization of diagnostic products using the DiagnoCure PCA3 gene technology for prostate cancer.

IBEX Technologies Inc. company develops and sells a series of proprietary enzymes for use in pharmaceutical research, particularly for arthritis and oncology. It markets diagnostic assays for use in arthritis tests that monitor the deterioration of cartilage; other assays monitor the rebuilding of cartilage. IBEX also provides enzymes for use as reagents used in hemostasis monitoring devices (for blood coagulation detection during certain surgical procedures). The majority of the company's sales are in the US (50%), followed by Europe and Canada, where sales revenues are split evenly. The publicly-traded company, founded in 1972, is led by CEO Paul Baehr.

BioGenex Laboratories, Inc. company was founded in 1981 and is based in San Ramon, California. BioGenex Laboratories Inc provides automated systems that streamline operations in molecular and cellular pathology laboratories. It offers Xmatrx Dx, an automated staining system that includes detection kits, primary antibodies, probes, reagents, and consumables for immunohistochemistry (IHC), in situ hybridization (ISH) and special stains (SS); i6000 that is an automated staining system designed for clinical diagnostics and research laboratories; EZ-Retriever System v.2, a microwave-based time and temperature controlled system designed to unmask the antigens on the formalin-fixed paraffin-embedded (FFPE) tissue sections; i500 Integrated Labeling System, a portable barcode solution, which creates barcode and text labeling for histology and cytology slides; and Xmatrx Rx, a biomarker assay development and analysis system that offers possibilities for translational and clinical research. The company also provides antibodies, antigen retrieval, ancillary reagents, detection systems, special stains, and tissue controls. In addition, it provides DNA/RNA synthesis labeling reagents, phosphoramidite, and branching phosphoramidites. The company serves reference laboratories, hospital laboratories, cancer treatment centers, university medical centers, group practices, and drug discovery laboratories in pharmaceutical and biotechnology firms, as well as oligonucleotide houses and academic institutions. BioGenex Laboratories Inc markets its products through distributors in Africa, Asia, Australia, Europe, the Middle East, North America, and South America.

INC Research is a contract research organization (CRO) that specializes in conducting clinical trials for drugs targeting cancer, infectious diseases, and central nervous system disorders. It also has a division devoted to pediatrics. Its services include scientific and medical consulting, study monitoring, project management, and regulatory support services. The CRO operates in more than 30 countries around the globe. Its DataSpectrum subsidiary helps researchers capture and manage clinical trial data. The company was formed in 1998 as a result of the merger between the Neuroclinical Trials Center and the Integrated Neuroscience Consortium.

Discovery Laboratories was founded in 1992 and is headquartered in Warrington, Pennsylvania. Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant replacement therapies (SRT) to treat respiratory disorders and diseases. The company's proprietary technology, KL4 Surfactant Technology, produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant. Its products include Surfaxin, a synthetic, peptide-containing surfactant for use in pediatric medicine; Surfaxin (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants; and Aerosurf, which is a KL4 Surfactant in aerosolized form to treat premature infants at risk for RDS. Discovery Laboratories also focuses on the development of Surfaxin to address bronchopulmonary dysplasia in premature infants, acute respiratory failure in children, cystic fibrosis, acute lung injury, and other diseases associated with the inflammation of the lung, such as asthma and chronic obstructive pulmonary disease. The company has a license agreement with Philip Morris USA Inc. to use its Capillary Aerosolization Technology for use with pulmonary surfactants for the respiratory diseases; and has a strategic alliance with Laboratorios del Dr. Esteve, S.A. to develop, market, and sell surfactant products in Andorra, Greece, Italy, Portugal, and Spain.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.